Haihong jin
Chief Scientific Officer Vitsgen Therapeutics, Inc.
Haihong Jin is Chief Scientific Officer of Vitsgen Therapeutics. She has over 25 years of drug discovery experience advancing therapies across oncology, metabolic disease, CNS and inflammation. She has discovered the first-in-class tryptophan hydroxylase (TPH) inhibitor, XERMELO for non-constipating irritable bowel syndrome which was approved in 2017. Meanwhile, she has led the Acyl-CoA Synthetase 5 (LX985) program which is entering an Exclusive License Agreement with Novo Nordisk in 2025. Her co-authored paper “Acyl-CoA Synthetase 5 Knockout and Inhibitors Protect Against Diet-Induced Obesity in Mice by Activating the Ileal Brake” has been selected as the Journal of the Endocrine Society Featured Article. Beyond this, she had led and invented ST-01156, a RBM 39 molecular glue, which is in phase 1 now.
Her recent work centers on Radioligand Therapy. Under her leadership, Vitsgen has completed two potential Best-in Class IND enabling studies and the third project is entering preclinical study.
Seminars
- Sharing the development journey of a PSMA-targeted radiopharmaceutical from preclinical development through to Phase I clinical evaluation
- Exploring key considerations when preparing regulatory submissions to the Chinese CDE and identifying opportunities to accelerate clinical entry
- Understanding the similarities and differences between CDE and FDA expectations for radiopharmaceutical development
- Highlighting practical lessons learned from generating the data package required to support successful first-in-human studies and future global development
